Search
Displaying 61–70 of 1045 results
-
Disease
Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2024 (July 1, 2023 – June 30, 2024)
-
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Research NewsThe Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
General thank you message for registering for an upcoming event.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Eye on the Cure Podcast | Episode 75: Sharon King
Eye on the CureSharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
Ongoing Foundation Fighting Blindness national webinars around the latest research for blinding diseases.
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
-
The Foundation’s grants and awards are critical and allow recipients to secure additional and often larger awards from other funding entities like the National Institute of Health.
.png)
